Correlation Between Mereo BioPharma and X4 Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Mereo BioPharma and X4 Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Mereo BioPharma and X4 Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Mereo BioPharma Group and X4 Pharmaceuticals, you can compare the effects of market volatilities on Mereo BioPharma and X4 Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Mereo BioPharma with a short position of X4 Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Mereo BioPharma and X4 Pharmaceuticals.

Diversification Opportunities for Mereo BioPharma and X4 Pharmaceuticals

0.62
  Correlation Coefficient

Poor diversification

The 3 months correlation between Mereo and XFOR is 0.62. Overlapping area represents the amount of risk that can be diversified away by holding Mereo BioPharma Group and X4 Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on X4 Pharmaceuticals and Mereo BioPharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Mereo BioPharma Group are associated (or correlated) with X4 Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of X4 Pharmaceuticals has no effect on the direction of Mereo BioPharma i.e., Mereo BioPharma and X4 Pharmaceuticals go up and down completely randomly.

Pair Corralation between Mereo BioPharma and X4 Pharmaceuticals

Given the investment horizon of 90 days Mereo BioPharma Group is expected to under-perform the X4 Pharmaceuticals. But the stock apears to be less risky and, when comparing its historical volatility, Mereo BioPharma Group is 4.77 times less risky than X4 Pharmaceuticals. The stock trades about -0.15 of its potential returns per unit of risk. The X4 Pharmaceuticals is currently generating about -0.02 of returns per unit of risk over similar time horizon. If you would invest  50.00  in X4 Pharmaceuticals on August 27, 2024 and sell it today you would lose (16.00) from holding X4 Pharmaceuticals or give up 32.0% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Mereo BioPharma Group  vs.  X4 Pharmaceuticals

 Performance 
       Timeline  
Mereo BioPharma Group 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Mereo BioPharma Group has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors.
X4 Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days X4 Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unfluctuating performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in December 2024. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Mereo BioPharma and X4 Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Mereo BioPharma and X4 Pharmaceuticals

The main advantage of trading using opposite Mereo BioPharma and X4 Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Mereo BioPharma position performs unexpectedly, X4 Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in X4 Pharmaceuticals will offset losses from the drop in X4 Pharmaceuticals' long position.
The idea behind Mereo BioPharma Group and X4 Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.

Other Complementary Tools

Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.